Short Interest in TherapeuticsMD, Inc. (NASDAQ:TXMD) Grows By 26.4%

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 29,700 shares, an increase of 26.4% from the October 15th total of 23,500 shares. Based on an average daily volume of 13,700 shares, the short-interest ratio is presently 2.2 days. Approximately 0.3% of the company’s stock are sold short.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the quarter. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 30.74% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of TherapeuticsMD in a report on Friday. They set a “hold” rating on the stock.

TherapeuticsMD Stock Down 4.1 %

Shares of TXMD opened at $1.40 on Friday. The stock has a 50 day moving average of $1.61 and a 200 day moving average of $1.78. TherapeuticsMD has a 12 month low of $1.36 and a 12 month high of $3.07.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.